谷歌浏览器插件
订阅小程序
在清言上使用

MM-355 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-Vrd) Transplant-Eligible (TE) Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study

Clinical Lymphoma Myeloma and Leukemia(2024)

引用 0|浏览11
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要